National Bank Keeps Their Buy Rating on Solaris Resources (SLSR)
In a report released today, Shane Nagle from National Bank maintained a Buy rating on Solaris Resources (SLSR – Research Report), with a price target of C$12.50. The company's shares closed today at $4.40.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Nagle is a 5-star analyst with an average return of 21.2% and a 70.04% success rate. Nagle covers the Basic Materials sector, focusing on stocks such as Agnico Eagle, Franco-Nevada, and Kinross Gold.
Solaris Resources has an analyst consensus of Strong Buy, with a price target consensus of $9.62.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
TipRanks' ‘Perfect 10' Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
Imagine planning a cross-country road trip with thousands of potential stops. You've got maps, reviews, GPS coordinates, weather forecasts – too much information, really. Some places look promising, others are hyped up but turn out to be duds. And without a smart guide, you're left second-guessing every turn. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter That's how investing can feel. Every stock is a destination, but figuring out which ones are worth the journey is overwhelming. Earnings, analyst opinions, insider trades – it's all useful, but hard to process when it comes at you from all directions. That's where TipRanks' Smart Score comes in. Think of it as your investment GPS. It's designed specifically to cut through the noise and highlight the most promising opportunities. Powered by AI, the system processes the massive flow of daily market data and distills it all into a single, simple number: a score from 1 to 10 that signals how likely a stock is to outperform in the months ahead. A 'Perfect 10' signals those stocks that deserve a closer look. So, let's go browsing through the top-scoring stocks on the TipRanks data platform. We can start with two that are ticking all the boxes, earning the 'Perfect 10' even in an uncertain market environment – and picking up investor attention for the right reasons. GDS Holdings (GDS) We'll start our look at 'Perfect 10' stocks with one of China's major data center holding firms, GDS Holdings. This company is an important player in China's growing technology industry, where it offers its customers a range of vital services. These include data center colocation, managed hosting, and managed cloud services. GDS's services are secure, reliable, and fault-tolerant—important attributes for a third-party provider. The company boasts that it brings value to the data center IT world, with data centers that feature plenty of net floor space, high power capacities, and multiple protective redundancies across mission-critical systems. The company is both carrier- and cloud-neutral, allowing its customers to access major telecom networks and public clouds. In its 24-year history of operations, GDS has built up a solid customer base, mainly composed of financial institutions, hyperscale cloud service providers, IT service providers, large internet firms, and telecom carriers. In addition, large domestic private sector and multinational corporations operating in China make use of GDS's services. This customer base is highly diverse, but GDS's customers are also known as highly demanding—meeting their needs is a sign of success for GDS. In addition to its operations in China, GDS owns a non-controlling stake of 35.6% in DayOne Data Centers Limited, which takes the development and operations of data centers and related services to the international markets. Turning to the company's financial results, we find that GDS realized $375.3 million in total revenues during 1Q25, in US currency. This figure was up 12% year-over-year, although it missed the forecast by $4.48 million. At the bottom line, GDS saw earnings of $0.48 per share in the quarter; in Chinese currency, this came to RMB3.47, and compared favorably to the net loss of RMB1.96 per share reported in 1Q24. Greg Miller, of Citizens JMP, covers this stock, and he is impressed by GDS's potential going forward. Pointing out the power capacity behind the company's data center operations, Miller goes on to outline the firm's attractive profile, writing, 'Following the near two-year slow down with companies taking more space, we now find the company poised to deliver as much as 900 MW of capacity over the next four years in China and yet another 700 MW of capacity outside of China in its international entity now called 'Day One.' We believe we are now back to a situation in which one should evaluate the total available capacity of its pipeline in order to assess its long-term value… With 900 MW domestic and 700 MW international to monetize, we believe consolidated revenues and EBITDA could double over the course of the next four years. With the C-REIT likely to be worth more than $30 per GDS share and the international company another $10, even before we fully assess the potential to sell through inventory, we continue to find the stock attractive for purchase.' In line with his description of the stock as 'attractive for purchase,' Miller rates the shares as Outperform (i.e., Buy), with a price target of $40 that implies an upside of 45% for the year ahead. (To watch Miller's track record, click here) GDS shares have a Strong Buy from the Street's analyst consensus, based on a unanimous 7 Buys. The shares are priced at $27.54, and their $37.19 average price target suggests that the stock will gain 35% on the one-year horizon. (See GDS stock forecast) BridgeBio Pharma (BBIO) Next on our list of 'Perfect 10s' is BridgeBio Pharma, a biomedical research company that is working on new treatments for rare and serious genetic diseases. The firm's targets are diseases with clear genetic drivers – conditions that are not just genetically linked, but are also known to be caused by single genetic mutations. The company points out that more than 10,000 such genetic disease conditions meet this description and affect tens of millions of patients around the world – but that there are fewer than 50 FDA-approved medications, making this a rich field for new biomedical research. BridgeBio has developed a proprietary drug development platform and takes a step-by-step approach to its research. The company first works to discover novel genetic disease targets and follows by creating medicines to alleviate symptoms and improve quality of life. The most important steps come next: bringing the drug candidates to the clinical trial and regulatory approval stages, and then moving on to commercialization. Currently, BridgeBio has seven trial programs in its drug development program. One of these, acoramidis, has reached the commercial stage, with approval from the FDA for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Phase 3 studies of the drug showed rapid and durable, statistically significant improvements in patients under treatment, and the drug was approved by the FDA in November of last year. The company is currently marketing acoramidis under the name Attruby. The treatment of TTR-related conditions has become something of a hot topic recently in the biopharmaceutical field. The treatment of ATTR-CM alone is expected to have a potential market worth approximately $16 billion by 2030 (according to Grand View Research), and that has attracted both Pfizer and Alnylam as well. Alnylam's drug Amvuttra was approved in 2022 and brought in $970 million in sales last year. From the perspective of BridgeBio investors, this only highlights the potential in this field. We should note that, in 1Q25, BridgeBio reported its first full quarter after the approval of Attruby and revealed that it had $36.7 million in quarterly product revenue from the drug. BridgeBio's sound position in a potentially rich field has caught the attention of Andy Chen from Wolfe Research. Chen writes of the company, 'BBIO is in a favorable position narratively amid the 'TTR craze' (refer to strong performance of Alnylam). Regardless of market size (which we cannot substantiate) and clinical profile (we believe a few points in clinical efficacy are simply there to satisfy buyside trades and will not strongly sway therapy selection), we are believers in Bridge's execution strategy commercially, with strong tailwind due to the awkward design of the US healthcare system (though we do find it odd that Bridge is not exercising its prerogative to disadvantage Alnylam via steps – perhaps Bridge is quietly pushing this expense onto AstraZeneca/Ionis). Near-term stock upside is likely if Bridge posts linear or better revenue trajectory.' Chen follows these comments by rating the stock as Outperform (i.e., Buy), and he supports that with a price target of $49, showing his confidence in a 16% one-year upside. (To watch Chen's track record, click here) It's clear that Wall Street likes this stock, as BridgeBio has a Strong Buy consensus rating based on 16 recent recommendations that include 15 Buys and 1 Hold. The stock is selling for $42.18, and the average target price is more optimistic than Chen will permit; at $60.27, the figure points toward a gain of 43% in the year ahead. (See BBIO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
40 minutes ago
- Business Insider
Veradigm (MDRX) Receives a Buy from TD Cowen
In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on Veradigm (MDRX – Research Report), with a price target of $8.00. The company's shares closed yesterday at $4.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rhyee covers the Healthcare sector, focusing on stocks such as Charles River Labs, CVS Health, and Icon. According to TipRanks, Rhyee has an average return of 1.2% and a 47.49% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Veradigm with a $5.00 average price target. The company has a one-year high of $11.80 and a one-year low of $3.00. Currently, Veradigm has an average volume of 210.6K.
Business Insider
an hour ago
- Business Insider
Wilsons Sticks to Its Buy Rating for SmartPay Holdings Limited (KX2)
Wilsons analyst Cameron Halkett maintained a Buy rating on SmartPay Holdings Limited (KX2 – Research Report) on June 23 and set a price target of A$1.20. The company's shares closed last Monday at €0.52. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Halkett is a 3-star analyst with an average return of 3.0% and a 52.08% success rate. Halkett covers the Financial sector, focusing on stocks such as OFX Group Ltd., HUB24 Limited, and Pinnacle Investment Management Group Limited. Currently, the analyst consensus on SmartPay Holdings Limited is a Moderate Buy with an average price target of €0.61.
